

INSIGHT

CC

CENTRAL NERVOUS SYSTEM

Is creatine a CNS neurotransmitter?

A range of experiments suggests that creatine, a molecule known for recycling ATP in muscle and brain tissue, may also function as a neurotransmitter in the central nervous system.

BHAGABAN MALLIK AND C ANDREW FRANK

Related research article Bian X, Zhu J, Jia X, Liang W, Yu S, Li Z, Zhang W, Rao Y. 2023. Evidence suggesting creatine as a new central neurotransmitter: presence in synaptic vesicles, release upon stimulation, effects on cortical neurons and uptake into synaptosomes and synaptic vesicles. *eLife* **12**:RP89317. doi: 10.7554/ eLife.89317

• ommunication in the nervous system relies on neurons transmitting signals to target cells. This process is facilitated by various chemicals, including neurotransmitters, neuromodulators and neuropeptides (Langley, 1905; Benfenati and Agnati, 1991; Lovinger, 2008). Identifying a new neurotransmitter is no small feat: such a discovery requires extensive investigation and validation, and it might take decades to integrate the collective contributions of many different research groups (Hökfelt, 2010; Contestabile, 2011). Moreover, neurotransmitters that act in peripheral tissues, like muscle, are easier to identify than those that act on the central nervous system (CNS). It is likely that many CNS neurotransmitters have not yet been identified (Curtis et al., 1959; Carlsson et al., 1962; Curtis and Watkins, 1963; Björklund et al., 1968; Andersson, 2000).

To be classified as a neurotransmitter, a molecule should meet several criteria: it needs to be stored within a synaptic vesicle in a neuron and be released upon neuronal stimulation; it needs to act upon a postsynaptic receptor; and afterwards, it needs to be removed or retrieved from the synaptic cleft (*Kandel et al., 2021*; *Purves, 2018; Radian et al., 1986; Pacholczyk et al., 1991*). Curiously, several molecules widely accepted as neurotransmitters only meet some, rather than all, of these criteria (*Curtis and Watkins, 1960; Felix and Künzle, 1974*). Accurately detecting candidate molecules within synaptic vesicles could represent a significant step towards identifying neurotransmitters with a higher certainty.

Now, in *eLife*, Yi Rao and colleagues at Peking University and other research centers in Beijing – including Xiling Bian, Jiemin Zhu and Xiaobo Jia as joint first authors – report data that potentially uncovers a new neurotransmitter within the mammalian brain (*Bian et al., 2023*). The researchers used a combination of mass spectrometry, genetics, biochemistry, immunostaining, electrophysiology, and electron microscopy to support this conclusion.

Starting with purified synaptic vesicles (SV) from mouse brains, Bian et al. detected several wellknown neurotransmitters in their samples, as well as creatine. The levels of SV creatine were higher than those of other known neurotransmitters, such as acetylcholine and serotonin, but lower than glutamate and gamma-aminobutyric acid (GABA). It has been known for decades that creatine is involved in recycling ATP in both muscle and brain tissue (Wyss and Kaddurah-Daouk, 2000; Brosnan and Brosnan, 2007; Wallimann et al., 2011). And more recently, researchers have suggested that it

© Copyright Mallik and Frank. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.



Figure 1. Schematic illustration of the synthesis, transport and release of creatine in neurons. A subtype of glial cell, known as an astrocyte (orange), likely synthesizes creatine molecules (red dots) through a process involving the amino acids glycine (Gly) and arginine (Arg), the enzymes AGAT and GAMT, and other compounds (GAA and SAM; **Roschel et al., 2021**). It is likely that the creatine molecules are then transported into a synaptic vesicle located in a presynaptic neuron that expresses a creatine transporter (CreaT) called SLC6A8. SNARE proteins (string-like structures) then mediate the release of the vesicles containing the creatine molecules into the synaptic cleft in a calcium-dependent manner, and the creatine molecules go on to bind to an as-yet unidentified creatine receptor (CreaR) on the postsynaptic neuron. It is possible that creatine molecules are also released directly by the astrocytes into the synaptic cleft between the neurons in a calcium-independent manner. AGAT: L-arginine: glycine amidinotransferase; GAA: guanidinoacetate; GAMT: guanidinoacetate methyltransferase; SAM: S-adenosylmethionine.

Image created with BioRender.com

might also have additional roles in brain function (Ohtsuki et al., 2002; Braissant et al., 2011).

The next step was to dissect the molecular mechanism of creatine function in neurons. Bian et al. demonstrated that creatine was released from stimulated coronal brain slices. Interestingly, creatine release was reduced in slices from mice lacking either the gene that codes for an enzyme called AGAT (which is necessary for creatine production), or the gene that codes for the SLC6A8 creatine transporter. Importantly, the Bian et al. also observed that creatine has an inhibitory effect on a subset of neurons. They also found that SLC6A8 can move creatine into synaptosomes (isolated synaptic structures that contain a machine that helps release neurotransmitters and large numbers of synaptic vesicles). Collectively, these results are consistent with creatine acting like a neurotransmitter and with AGAT and SLC6A8 supporting that function (*Figure 1*).

The work by Bian et al. goes beyond previous studies, which posited that creatine could have neurotransmitter-like properties (*Almeida et al.,* 2006; Peral et al., 2010). Nevertheless, questions remain for future work. Most notably, Bian et al. did not identify a specific postsynaptic receptor for creatine. The researchers speculate that there might be a metabotropic receptor (or receptors) for creatine (*Figure 1*). Another mystery is that most of the creatine release after high potassium stimulation occurs when there is no extracellular calcium present. This is not consistent with a neurotransmitter role for that portion of the release. Bian et al. speculate that astrocytes might be responsible because astrocytes contain high levels of an enzyme called GAMT, which is involved in the production of creatine. If this idea were correct, then astrocytic creatine could potentially serve a neuromodulatory role. One final puzzle is that AGAT and SLC6A8 are found in different cells in the brain. So if creatine were a neurotransmitter, it suggests a complex model of creatine being synthesized in one cell type and subsequently then transported to another cell type for release (*Figure 1*).

In summary, Bian et al. report that creatine is a possible neurotransmitter in the central nervous system and that it meets several textbook criteria for a neurotransmitter (*Kandel* et al., 2021; Purves, 2018). This is a potentially groundbreaking finding that could have implications for understanding brain function and neurotransmission. It may also open new areas of understanding Creatine Transporter Deficiency, which manifests as a collection of intellectual disabilities, language delays and other neurological disorders that are associated with defective SLC6A8 (*Salomons et al., 2003*).

Bhagaban Mallik is in the Department of Anatomy and Cell Biology, University of Iowa, Iowa City, United States

b https://orcid.org/0000-0001-7637-3338

C Andrew Frank is in the Department of Anatomy and Cell Biology, University of Iowa, Iowa City, United States

andy-frank@uiowa.edu
https://orcid.org/0000-0001-9599-421X

Competing interests: The authors declare that no competing interests exist.

Published 16 October 2023

References

Almeida LS, Salomons GS, Hogenboom F, Jakobs C, Schoffelmeer ANM. 2006. Exocytotic release of creatine in rat brain. *Synapse* **60**:118–123. DOI: https://doi.org/10.1002/syn.20280, PMID: 16715490 Andersson KE. 2000. Neurotransmitters: central and peripheral mechanisms. *International Journal of Impotence Research* **12 Suppl 4**:S26–S33. DOI: https://doi.org/10.1038/sj.ijir.3900574, PMID: 11035383

Benfenati F, Agnati LF. 1991. Communication and computation in the central nervous system. *Functional Neurology* **6**:202–209 PMID: 1683850.

Bian X, Zhu J, Jia X, Liang W, Yu S, Li Z, Zhang W, Rao Y. 2023. Evidence suggesting creatine as a new central neurotransmitter: presence in synaptic vesicles, release upon stimulation, effects on cortical neurons and uptake into synaptosomes and synaptic vesicles. *eLife* **12**:RP89317. DOI: https://doi.org/10.7554/eLife.89317.1 **Björklund A**, Ehinger B, Falck B. 1968. A method for differentiating dopamine from noradrenaline in tissue sections by microspectrofluorometry. *The Journal of Histochemistry and Cytochemistry* **16**:263–270. DOI: https://doi.org/10.1177/16.4.263, PMID: 5656462 **Braissant O**, Henry H, Béard E, Uldry J. 2011. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. *Amino Acids* **40**:1315–1324. DOI: https://doi.org/10.1007/s00726-011-0852-z, PMID: 21390529

Brosnan JT, Brosnan ME. 2007. Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annual Review of Nutrition **27**:241–261. DOI: https:// doi.org/10.1146/annurev.nutr.27.061406.093621, PMID: 17430086

Carlsson A, Falck B, Hillarp NA. 1962. Cellular localization of brain monoamines. *Acta Physiologica Scandinavica* **56**:1–28.

Contestabile A. 2011. The history of the cholinergic hypothesis. *Behavioural Brain Research* **221**:334–340. DOI: https://doi.org/10.1016/j.bbr.2009.12.044, PMID: 20060018

Curtis DR, Phillis JW, Watkins JC. 1959. Chemical excitation of spinal neurones. *Nature* **183**:611–612. DOI: https://doi.org/10.1038/183611a0, PMID: 13632811

Curtis DR, Watkins JC. 1960. The excitation and depression of spinal neurones by structurally related amino acids. *Journal of Neurochemistry* **6**:117–141. DOI: https://doi.org/10.1111/j.1471-4159.1960. tb13458.x, PMID: 13718948

Curtis DR, Watkins JC. 1963. Acidic amino acids with strong excitatory actions on mammalian neurones. *The Journal of Physiology* **166**:1–14. DOI: https://doi.org/ 10.1113/jphysiol.1963.sp007087, PMID: 14024354

Felix D, Künzle H. 1974. Iontophoretic and autoradiographic studies on the role of proline in nervous transmission. *Pflugers Archiv* **350**:135–144. DOI: https://doi.org/10.1007/BF00586233, PMID: 4368845

Hökfelt T. 2010. Looking at neurotransmitters in the microscope. *Progress in Neurobiology* **90**:101–118. DOI: https://doi.org/10.1016/j.pneurobio.2009.10.005, PMID: 19853008

Kandel ER, Koester JD, Mack SH, Siegelbaum SA. 2021. *Principles of Neural Sciences* (6th Edition.). McGraw-Hill.

Langley JN. 1905. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. *The Journal of Physiology* **33**:374–413. DOI: https://doi.org/10.1113/jphysiol.1905.sp001128, PMID: 16992819

Lovinger DM. 2008. Communication networks in the brain: neurons, receptors, neurotransmitters, and alcohol. *Alcohol Research & Health* **31**:196–214 PMID: 23584863.

Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K-I, Terasaki T. 2002. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. *Journal of Cerebral Blood Flow and Metabolism* **22**:1327–1335. DOI: https://doi.org/10.1097/01.WCB.0000033966. 83623.7D, PMID: 12439290

Pacholczyk T, Blakely RD, Amara SG. 1991. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. *Nature* **350**:350–

354. DOI: https://doi.org/10.1038/350350a0, PMID: 2008212

Peral MJ, Vázquez-Carretero MD, Ilundain AA. 2010. Na(+)/Cl(-)/creatine transporter activity and expression in rat brain synaptosomes. *Neuroscience* **165**:53–60. DOI: https://doi.org/10.1016/j.neuroscience.2009.10. 001, PMID: 19804817

Purves D. 2018. *Neuroscience* New York: Oxford University Press.

Radian R, Bendahan A, Kanner BI. 1986. Purification and identification of the functional sodium- and chloride-coupled gamma-aminobutyric acid transport glycoprotein from rat brain. *The Journal of Biological Chemistry* **261**:15437–15441 PMID: 3536902.

Roschel H, Gualano B, Ostojic SM, Rawson ES. 2021. Creatine supplementation and brain health. *Nutrients*

13:586. DOI: https://doi.org/10.3390/nu13020586, PMID: 33578876

Salomons GS, van Dooren SJM, Verhoeven NM, Marsden D, Schwartz C, Cecil KM, DeGrauw TJ, Jakobs C. 2003. X-linked creatine transporter defect: an overview. *Journal of Inherited Metabolic Disease* 26:309–318. DOI: https://doi.org/10.1023/a: 1024405821638, PMID: 12889669

Wallimann T, Tokarska-Schlattner M, Schlattner U. 2011. The creatine kinase system and pleiotropic effects of creatine. *Amino Acids* **40**:1271–1296. DOI: https://doi.org/10.1007/s00726-011-0877-3, PMID: 21448658

Wyss M, Kaddurah-Daouk R. 2000. Creatine and creatinine metabolism. *Physiological Reviews* 80:1107–1213. DOI: https://doi.org/10.1152/physrev. 2000.80.3.1107, PMID: 10893433